Delivery Order SPE2DB24D2100-SPE2DB24FBCKE

Award Date 7/11/24
Potential Completion Date 7/12/24
Potential Value $35K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award is for the delivery of Ozempic 0.25-0.5 mg/dose pens, a medication used for diabetes management, to the Defense Logistics Agency (DLA) Troop Support Medical. The contract, valued at $19,875.89, was awarded to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) held by Amerisourcebergen's parent company, Cencora, Inc., with the DLA, valued...
The federal contract award is for the delivery of Ozempic 0.25-0.5 mg/dose pens, a medication used for diabetes management, to the Defense Logistics Agency (DLA). The $1,959.48 firm fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor. This award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by AmerisourceBergen with the DLA Troop Support Medical, which serves as a primary vehicle for providing a comprehensive...
This federal contract award is for the delivery of Ozempic 0.25-0.5 mg/dose pen 3ml, a medication used for the treatment of diabetes. The contract, valued at $1,161.08, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The delivery order contract has a firm fixed price and an ultimate completion date of April 10, 2024. The contract does not have a set-aside designation, indicating open competition. AmerisourceBergen maintains...
This federal contract award is for the delivery of Ozempic 0.25-0.5 mg/dose pens, a pharmaceutical product used in the treatment of diabetes. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract has a firm fixed price of $5,551.21 and a completion date of September 24, 2024. It is a delivery order contract, indicating it is part of a larger Indefinite Delivery Contract (IDC) vehicle....
This federal contract award is for the delivery of Ozempic 0.25-0.5 mg/dose pens, a medication used to treat diabetes. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) Troop Support Medical. The contract is a delivery order with a firm fixed price of $3,262.56 and a completion date of November 21, 2024. This award is not designated as a set-aside contract. AmerisourceBergen holds a significant Indefinite Delivery...
This federal contract award is for the delivery of Ozempic 0.25-0.5 mg/dose pens, a prescription medication used to treat type 2 diabetes. The $9,042.10 firm-fixed-price contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA). The contract has an ultimate completion date of August 26, 2024 and does not have a set-aside designation, indicating it was competitively awarded. AmerisourceBergen holds a significant $999,999,999...
The provided federal contract award is for the delivery of Ozempic 0.25-0.5 mg/dose pens with a 3 mL capacity. The contract was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, by the Defense Logistics Agency (DLA), a defense agency. The contract is a Delivery Order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a...
This federal contract award is for the delivery of Ozempic 0.25-0.5 mg/dose pen 3ml, a medication used to manage diabetes. The contract, valued at $5,221.08, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) on May 25, 2023. The contract is a delivery order with a firm fixed price and an ultimate completion date of May 26, 2023. There was no set-aside designation for this award. AmerisourceBergen holds significant Indefinite...
This federal contract award is for the delivery of 0.25-0.5 mg/dose pens of the pharmaceutical product Ozempic, a diabetes medication, to the Defense Logistics Agency (DLA). The $38,462.65 fixed-price delivery order was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, on July 10, 2025 with a completion date of July 11, 2025. The contract is not set aside and is part of a larger $999,999,999.00 Indefinite Delivery Contract (IDC) that AmerisourceBergen holds with the DLA...
This federal contract award is for the delivery of Ozempic 0.25-0.5 mg/dose pens with a 3 ml capacity. The contract, valued at $3,531.84, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor, by the Defense Logistics Agency (DLA) on November 6, 2024. The contract has a completion date of November 7, 2024 and is a firm fixed-price delivery order. The contract is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC)...
  • SPE2DB24D2100
    Indefinite Delivery Contract
  • SPE2DB24D2100-SPE2DB24FBCKE
    Delivery Order

This federal contract award is for the delivery of Ozempic 0.25-0.5 mg/dose pens, a pharmaceutical product used in the treatment of diabetes. The contract, valued at $35,223.56, was awarded to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 with the Defense Logistics Agency (DLA) Troop Support Medical, which serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has no set-aside designation, indicating open competition. The DLA, a defense agency, is the funding agency for this contract, which has an ultimate completion date of July 12, 2024.

Generated 5/17/25, 9:46 AM